On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.

Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.

Travere Therapeutics has begun a critical Phase 3 study of Pegtibatinase in the management of Classical Homocystinuria (HCU).

The fractional dose comes from the same full dose vaccine. It has been given to millions of people to prevent yellow fever in the past.

Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3-mediated NRG1 signaling in NRG1+ cancer.

In the European Union (EU), Compassionate use is a treatment option that allows the use of an unauthorised medicine.

Rezolute has commenced a pivotal Phase 3 clinical trial for its investigative drug, RZ358, aimed at treating patients with Congenital Hyperinsulinism.

Here are the open status categories for FDA postmarketing requirements and commitments listed.

SGLT2 inhibitors not only can effectively lower blood sugar, but also bring significant cardiorenal protective effects.

PAES, as mandated by EU Commission Delegated Regulation No 357/2014, refers to an efficacy study required by a Competent Authority under any of the specified conditions outlined in the regulation.

Mission Therapeutics reveals that the FDA has given the green light to start a Phase II study for their prime candidate, MTX652, targeting Acute Kidney Injury.

Rolling Review is a process used by the US Food and Drug Administration (FDA) to expedite the review of new drug applications.